Our Exosome-Oligonucleotide Conjugation Services support biotechnology teams, pharmaceutical research groups, delivery-platform developers, and academic laboratories developing extracellular vesicle systems for oligonucleotide transport, surface engineering, and functional studies. Depending on the research objective, oligonucleotides can be associated with vesicles through covalent surface conjugation, lipid-mediated membrane anchoring, affinity-based attachment, or loading into the vesicle interior. Each configuration introduces different requirements for oligonucleotide chemistry, vesicle handling, purification, and analytical verification.
We integrate oligonucleotide design and modification with exosome and small extracellular vesicle handling, conjugation strategy development, free-oligonucleotide removal, vesicle characterization, and application-focused testing. Projects can support siRNA, antisense oligonucleotides, miRNA-related reagents, DNA oligonucleotides, aptamers, and other research oligos. Our workflow is designed around the specific cargo, desired localization, attachment stability, downstream assay, and material constraints rather than applying a single loading method to every exosome-oligonucleotide project.
Surface Attachment or Internal Loading: An oligonucleotide displayed on the outer membrane serves a different experimental purpose from one protected inside a vesicle. We evaluate whether the project requires accessible surface oligonucleotides, membrane-anchored cargo, or protected intravesicular loading before selecting the conjugation chemistry and analytical strategy.
Preserving Vesicle Integrity: Electroporation, chemical functionalization, hydrophobic anchors, buffer changes, and purification steps can alter particle size, aggregation behavior, or membrane properties. Process conditions therefore need to be optimized together with the vesicle source and oligonucleotide chemistry instead of focusing only on apparent conjugation yield.
Separating Free Oligonucleotide: Residual unbound oligonucleotide can produce misleading fluorescence, hybridization, uptake, or functional signals. Our workflows incorporate appropriate fractionation and washing strategies so that conjugate-associated signals can be distinguished from free cargo carried through the preparation.
Confirming Cargo Location: Total oligonucleotide detected in an exosome-containing fraction does not by itself establish whether the cargo is surface-bound, membrane-associated, or protected within the vesicle. We plan nuclease-accessibility, membrane-disruption, and cargo-quantification controls where appropriate to obtain a more interpretable picture of conjugate architecture.
Connecting Uptake With Function: Cellular association or fluorescent uptake does not necessarily demonstrate productive oligonucleotide delivery. When required, our broader drug delivery platform can connect vesicle uptake studies with oligonucleotide-dependent molecular readouts, helping research teams distinguish internalization from functional cargo transfer.
Exosome-oligonucleotide conjugation projects can vary substantially in cargo length, charge, backbone chemistry, modification pattern, vesicle source, and desired cargo orientation. Our service workflow is therefore configured around the experimental purpose of the conjugate and the evidence needed to verify that the intended construct has been produced.
Projects may begin with customer-supplied vesicles or oligonucleotides, or can be coordinated with our oligonucleotide services and exosome RNA delivery services. Attachment chemistry, loading conditions, purification, analytical controls, and functional evaluation are selected as an integrated development plan.
The optimal exosome-oligonucleotide engineering strategy depends on where the oligonucleotide should reside, how stable the association needs to be, and what downstream experiment will be used. The matrix below summarizes practical differences among commonly considered approaches.
| Strategy | Construct Configuration | Useful For | Key Development Considerations | Verification Focus |
| Bioorthogonal Surface Conjugation | Reactive oligonucleotide coupled to complementary chemical handles presented on the vesicle surface | Stable surface display, DNA handles, targeting oligos, aptamer presentation, tracking constructs | Reactive-group density, linker length, reaction compatibility, membrane preservation, purification | Surface accessibility, oligonucleotide association, particle size and integrity |
| Lipid-Anchor Insertion | Cholesterol- or other hydrophobe-modified oligonucleotide inserted into the lipid membrane | Rapid membrane functionalization, modular surface display, screening studies | Anchor structure, spacer design, desorption or redistribution, cargo density, aggregation | Post-purification retention, surface accessibility, vesicle characteristics |
| Affinity/Hybridization Anchoring | Oligonucleotide connected through an affinity ligand, anchor strand, or complementary nucleic acid handle | Modular assembly, exchangeable cargo, multicomponent research constructs | Binding affinity, duplex stability, orientation, competing interactions, reversibility | Binding specificity, displacement behavior, accessible cargo |
| Electroporation-Assisted Loading | Oligonucleotide introduced into or associated with vesicles through transient membrane permeabilization | siRNA, selected ASO, and short-RNA loading studies | Cargo aggregation, electrical conditions, buffer composition, vesicle recovery, membrane perturbation | Free-cargo removal, nuclease protection, particle characteristics, cargo recovery |
| Passive Hydrophobic Loading | Hydrophobically modified oligonucleotide associated with the vesicle membrane during controlled incubation | Chemically modified short oligonucleotides and comparative formulation studies | Hydrophobic modification, incubation ratio, membrane partitioning, surface versus internal distribution | Vesicle-associated cargo, accessible cargo fraction, stability after purification |
Reliable interpretation requires more than demonstrating that oligonucleotide and vesicle signals occur in the same preparation. Characterization should address the vesicle population, cargo quantity, residual free oligonucleotide, cargo accessibility, and any processing-induced changes relevant to the intended experiment.
| Attribute | Why It Matters | Typical Approaches | Decision Supported | Project Stage |
| Particle Size & Concentration | Detect changes in vesicle population or aggregation after conjugation and purification | Nanoparticle tracking or other particle-analysis methods | Process-condition comparison and preparation consistency | Development / QC |
| Vesicle Characteristics | Determine whether the preparation retains expected extracellular-vesicle-associated attributes | Marker analysis, morphology assessment, particle-based characterization | Suitability for downstream research | Development / QC |
| Total Oligonucleotide | Estimate how much cargo is associated with the purified vesicle-containing fraction | Fluorescence, hybridization-based assays, sequence-specific quantification, or chemistry-dependent methods | Condition ranking and material normalization | Development / QC |
| Free Oligonucleotide | Identify residual unbound cargo that could distort downstream uptake or functional measurements | Fraction analysis, size-based separation controls, cargo-specific quantification | Purification optimization and data interpretation | Development / QC |
| Surface Accessibility | Determine whether an oligonucleotide is exposed on the outside of intact vesicles | Nuclease-accessibility, hybridization, affinity-probe, or related surface-access assays | Confirmation of surface-display architecture | Characterization |
| Protected Cargo | Distinguish protected oligonucleotide from externally accessible cargo | Nuclease challenge with intact-vesicle and membrane-disruption controls | Assessment of intravesicular or membrane-protected loading | Characterization |
| Conjugate Stability | Determine whether oligonucleotide association is maintained during storage or assay-relevant incubation | Time-point analysis, buffer challenge, post-incubation separation and cargo measurement | Handling-condition and experimental-window selection | Development |
| Functional Transfer | Establish whether vesicle-associated cargo produces the intended sequence-dependent research readout | Uptake studies combined with knockdown, reporter, hybridization, or target-specific assays | Candidate selection and delivery-system optimization | Application Testing |
Our workflow coordinates oligonucleotide chemistry with extracellular vesicle processing so that conjugation conditions, purification, analytical controls, and downstream testing are planned as one research program. Individual steps are adjusted according to cargo type, vesicle source, attachment route, available material, and required deliverables.
Define the oligonucleotide type, sequence, modifications, vesicle source, desired cargo location, downstream model, and analytical requirements. Customer-supplied materials are reviewed for compatibility, while projects requiring additional synthesis or vesicle preparation are coordinated before conjugation begins.
Select surface conjugation, lipid anchoring, affinity attachment, or intravesicular loading according to the research objective. Appropriate controls for free oligonucleotide, untreated vesicles, cargo accessibility, purification, and functional interpretation are incorporated into the project plan.
Prepare the required oligonucleotide functional groups, spacers, hydrophobic anchors, or labels and establish the vesicle preparation conditions. Baseline particle and cargo measurements can be collected when needed to provide reference points for post-conjugation comparisons.
Execute the selected attachment or loading process and evaluate key variables such as cargo-to-vesicle ratio, reaction time, buffer environment, temperature, or processing intensity. Conditions are judged by the combined behavior of oligonucleotide association, material recovery, and vesicle quality.
Separate engineered vesicles from unbound oligonucleotide and other soluble components, then perform the agreed analytical tests. Where relevant, accessibility and membrane-disruption controls are used to investigate whether cargo is surface-exposed or protected by the vesicle membrane.
Complete application-focused testing when included in the project, review results across conjugation and vesicle parameters, and provide the agreed materials and data package. Technical discussion can support interpretation, candidate selection, and planning of subsequent research experiments.
Service flow of exosome-oligonucleotide conjugation.
Exosome-oligonucleotide development sits at the interface of nucleic acid chemistry, membrane engineering, particle purification, and delivery biology. Our service model emphasizes coordinated decision-making across these areas so that conjugate design and analytical interpretation remain aligned with the actual research question.
Exosome-oligonucleotide conjugates provide configurable tools for studying nucleic acid delivery, extracellular vesicle engineering, surface recognition, and sequence-specific biological responses. The preferred construct architecture depends on whether the oligonucleotide is intended to function as cargo, a surface ligand, a molecular handle, or an analytical reporter.
Whether your project requires a surface-displayed DNA handle, cholesterol-anchored oligonucleotide, exosome-associated siRNA, protected ASO cargo, miRNA reagent, or a custom extracellular-vesicle engineering strategy, we can help define a technically appropriate route from material selection through conjugation and verification. Share your oligonucleotide type, vesicle source, intended cargo location, downstream assay, and available starting material, and our team can evaluate attachment options, purification requirements, analytical controls, and research deliverables. Contact us to discuss your exosome-oligonucleotide conjugation requirements.
Exosome-oligonucleotide conjugation involves attaching oligonucleotides to exosomes, which serve as carriers to protect and deliver nucleic acids to specific cells or tissues. This technique is widely used in nucleic acid-based therapies and precision medicine.
The conjugation process typically involves modifying the surface of exosomes or oligonucleotides with reactive groups, followed by chemical or bioengineering techniques like click chemistry or lipid-based methods to bind them. This results in a stable conjugate with enhanced delivery capabilities.
Exosome-oligonucleotide conjugates are used in RNA interference (RNAi) for gene silencing, precise gene editing, vaccine development, targeted drug delivery, and as biomarkers for diagnostics and prognostics.
Exosomes can be isolated from various cell types, including immune cells, stem cells, cancer cells, or specific tissue types. BOC Sciences offers a range of exosome options for custom conjugation services.
Loading ......
